Familial Mediterranean fever: Unusual age of presentation and the role of genetic diagnosis by Nakhaei, S. et al.
Arch Iranian Med 2005; 8 (0): 56 – 59   
Archives of Iranian Medicine, Volume 8, Number 1, January 2005 56 
  
 
FAMILIAL MEDITERRANEAN FEVER: UNUSUAL AGE OF 
PRESENTATION AND THE ROLE OF GENETIC DIAGNOSIS 
 
Shahrbanoo Nakhaei MD*, Elham Talachian MD•*, Ali Bidari MD** 
 
 
Familial Mediterranean fever (FMF) is a genetic disease characterized by periodic fever and/or 
painful inflammatory manifestations. Repeated attacks at irregular intervals and in an unpredictable 
sequence are typical of the disease. Most of the patients become symptomatic between ages 5 to 
15 years. Rarely, the disease may manifest as early as during the first year. 
Until recently, the diagnosis of FMF was mainly based on the presence of typical clinical picture 
and dramatic response to colchicine. Recent insight to the genetic basis of the disease has made 
DNA study available for diagnosis of FMF. We report a 20-month-old Iranian boy with recurrent 
attacks of abdominal pain and fever since the 4th month of birth. A molecular analysis was carried 
out, confirming mutation of the FMF-gene. 
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Introduction 
 
amilial Mediterranean fever (FMF) is an 
inherited, recurrent inflammatory disease 
prevalent among people of the near East, 
Arabs, Turks, Armenians, and Sephardic Jews. It is 
transmitted as an autosomal recessive trait. 
Symptoms usually appear between 5 and 15 years 
of age, but may begin earlier. The febrile, painful 
attacks are the hallmark of the disease and 
characterized by marked elevation of body 
temperature, acute inflammation of peritoneum, 
synovia or pleura, a duration of 12 to 48 hours, and 
complete health between attacks. Repeated attacks 
at irregular intervals and in an unpredictable 
sequence are typical of the disease.1 
 The most frequent manifestation is the painful, 
usually febrile abdominal attack, experienced by 
90% of patients; in 68% of them it is the presenting 
sign.2 Other less frequent manifestations include 
arthritis  (75%),3  pleuritis  (45%),  myalgia  (20%), 
erysipelas—like erythema (11%), orchitis, 
headache, meningitis, convulsion,4 adhesive small 
bowel obstruction (3%),5 mild splenomegaly, 
hepatomegaly, Henoch-Shonlein purpura (5%), 
polyarteritis nodosa (1%),6 and recurrent 
hyperbilirubinemia.7 
The most ominous complication of FMF is 
amyloidosis, potentially leading to chronic renal 
failure.8 Laboratory abnormalities are usually 
found during attacks and include leukocytosis (up 
to 30,000/mm3), high ESR, and elevated acute 
phase reactants.9 Attacks of FMF can be prevented 
by prophylactic colchicine therapy at a dose of 
0.02 to 0.03 mg/kg/24 hr (maximum of 2 mg/24 
hr) in one or two divided doses.10 
Until recently the diagnosis of FMF was based 
on the typical clinical picture and the dramatic 
response to colchicine therapy. Several sets of 
criteria have been proposed for the diagnosis of 
FMF.11-16 None of the existing criteria have 
become widely accepted and only one has been 
based on statistical evaluation with defined 
sensitivity and specificity. 16 The diagnosis of FMF 
has been revolutionized since 1997, when missense 
mutations in the Mediterranean fever gene 
(MEFV) on chromosome 16 were found to be 
responsible for the disease. 17 – 21 
We report an Iranian male infant with recurrent 
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attacks of abdominal pain and fever, who finally 
was confirmed to have FMF by DNA study. 
 
Case Report 
 
A 20-month-old boy presented to the hospital 
because of recurrent abdominal pain. The patient 
had been well until the age of 4 months, when he 
began to have two or three bouts of abdominal pain 
weekly. The abdominal pain lasted about 30 
minutes and was accompanied by irritability, 
restlessness, crying, and nonprojectile vomiting. 
These symptoms were followed by fever in the 
range of 39 to 40°C, which was continued for 16 to 
24 hours. The episodes repeated roughly every 
three days. Antipyretics such as acetaminophen 
caused partial relief of the symptoms. During these 
episodes there were no associated symptoms or 
other complaints, and between attacks the patient 
was well. He had no history of chronic diarrhea, 
vomiting, or weight loss.  
He was a full-term infant with a birth weight of 
3.3 kg. His Apgar score was 9 at 5 minutes. He 
was breastfed until 20 month of age. His 
immunizations were up to date. There was a 
history of hypertension, atrial septal defect, and 
ovarian cyst among the patient’s relatives. There 
was no family history of hereditary disorders, 
hemoglobinopathies, periodic fever, or abdominal 
pain syndromes. The boy was 85 cm tall (50% of 
percentile) and weighed 12.5 kg (60% of 
percentile).  
Physical examination was normal and showed 
no abdominal tenderness or organomegaly. The 
results of laboratory studies are shown in Tables    
1 – 3. Repeated peripheral blood smears were 
negative for Borrelia and malaria. Chest X-ray, 
abdominal ultrasonography, electroencephalo-
graphy, brain CT-scan without contrast, and 
barium enema were normal.  
Fulfilling the diagnostic criteria of Livneh et 
al16 and based on the clinical presentations and 
laboratory data, the diagnosis of FMF was 
proposed and in June of 1998 he was started on 
colchicine at a daily dose of 0.25 mg, after which 
the pain episodes became less frequent with 
intervals of 10 to 30 days. 
He was referred to Children’s Medical Practice, 
Johns Hopkins Bayview Medical Center on March 
19, 1999 for genetic analysis. Genetic testing for 
FMF was performed at the National Institutes of 
Health, Department of Health and Human 
Services, Bethesda, Maryland. The MEFV gene 
mutations were investigated in the patient. DNA 
was extracted from the peripheral blood 
lymphocytes according to the standard procedures. 
Mutation identification was performed with two 
previously-described PCR-based methods: the 
amplification refractory mutation system (ARMS) 
and restriction-enzyme analysis.22 – 26 As a result, 
two FMF-associated mutations in patient’s DNA 
sample were identified. He was tested for a panel 
of 13 known FMF mutations and found to be a 
carrier for the M694V and R761H mutations. This 
finding strongly supported the diagnosis of FMF. 
Subsequently, the colchicine dose increased to 1 
mg daily and abdominal pain episodes were 
completely resolved. 
 
Discussion 
 
The constellation of typical symptoms and 
signs in this 20-month-old boy as well as his 
susceptible ethnic background suggested the 
diagnosis of FMF. The unusual age of 
presentation, however, and the incomplete 
response to initial management by colchicine (0.25 
mg per day) were not so reassuring. Therefore, the 
patient was subjected to genetic study, which 
ultimately confirmed the diagnosis. 
Although the peculiar ethnic restriction and the 
familial aggregation in FMF had suggested a 
genetic etiology, it was not until 1997 when 
mutation in the gene MEFV was distinctly found to 
be responsible for the disease.25, 27 The gene is 
Table 1. Hematological values. 
Variable  Value 
Hb (g/dL) 12.2 
Hematocrit (%) 34.7 
ESR (mm/hr) 31 
RBC (per mm3) 4,900,000 
WBC (per mm3) 12,400 
Platelet count (per mm3) 469,000 
WBC Differential count (%)  
Neutrophils 77 
Lymphocytes 21 
Monocytes 2 
Eosinophils 2 
Table 2. Blood chemical values. 
Variable Value Normal range 
BUN (mg/dL)  5 5 – 18 
Creatinine (mg/dL) 0.5 0.3 – 0.7 
Calcium (mg/dL) 9.4 8.8 – 10.8 
Phosphorus (mg/dL) 4.5 3.8 – 6.5 
AST (U/L) 43 5 – 46 
ALT (U/L) 25 5 – 46 
LDH (U/L) 648 109 – 245 
Alkaline phosphatase 390 15 – 113 
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located on chromosome 16 and contains 10 exons 
and 781 codons.28 So far, 29 mutations, mostly 
located in the last exon, have been identified to be 
associated with FMF. Five of them account for up 
to 91% of FMF chromosomes that are: V726A, 
M694V, M680I, M694I, and B148Q.29, 30 
In our case, DNA study showed two mutations 
in MEFV alleles identified as R761H and M694V. 
The latter is one of the known prevalent mutations. 
It has been known that the frequencies and 
distribution of mutations, vary between different 
ethnic groups.31 – 34 While there is no data to 
demonstrate that these differences may have a role 
in phenotypic characteristics of FMF patients (i.e. 
causes different kinds of symptoms in individual 
patients), there are some evidence to relate the 
diversity of mutations to severity of the disease. 
For instance, it has been suggested that the 
presence of homozygous M694V mutation is 
significantly associated with a more severe form of 
disease characterized by earlier age of presentation 
and more frequent and prolonged abdominal 
attacks. Homozygousity for M694V mutation 
predominates among North African Jews and is 
associated with a severe course and more guarded 
prognosis. This mutation is less common among 
Arabs and, when present, occurs almost only in 
heterozygous form.35 The detection of M694V 
mutation in our case not only is consistent with 
diagnosis of FMF but also may explain the 
increased disease severity characterized by the 
early age of presentation and high frequency of 
painful abdominal attacks. 
The gene MEFV encodes for a 781-amino acid 
protein called pyrin.36 Homology searches indicate 
that pyrin is a new member of the RetRo gene 
family and suggests that pyrin itself may be a 
transcription factor presumably regulating the 
expression of target genes, at least some of which 
are probably involved in the suppression of 
inflammation. The gene is expressed in 
neutrophils, but not lymphocytes and monocytes. 
Therefore, it is not surprising that neutrophils are 
the main inflammatory cells involved in FMF 
attacks and colchicine, which specifically inhibits 
polymorphonuclear leukocyte function, is so 
effective in preventing the attacks.37 
Sixty-five percent of patients enjoy complete 
remission of attacks after treatment with 
colchicine.38 Partial remission, defined as either a 
significant decrease in the frequency and severity 
of all forms of attacks or the remission of one form 
(usually abdominal) but not of another (usually 
arthritic) is experienced by the rest 30%. The 
response to colchicine could be dose-dependent, 
although the gastrointestinal side effects may limit 
achieving the optimal dose.39 The clinical response 
to colchicine should be considered as a strong 
evidence for diagnosis of FMF. Our case 
experienced a partial response on 0.25 mg daily 
colchicine doses. A complete clinical remission 
was observed by increasing the dose to 1 mg per 
day, further supporting the diagnosis. 
In summary, the clinical suspicion of FMF in 
this 20-month-old Iranian boy was confirmed by 
DNA study and complete clinical response to 
colchicine. Molecular analysis of FMF should 
complement the investigation of at least a subset of 
patients with difficult diagnosis. This test enables a 
definite diagnosis of the disease and may promote 
the diagnosis and treatment of patients with an 
unusual or incomplete clinical picture of FMF.40, 41 
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